wire - news in brief
« BACK
Health - Pharmacology - 22.06.2021
Health - Life Sciences - 22.06.2021
Pharmacology - Health - 18.06.2021
Health - Pharmacology - 16.06.2021 
How do immune cells get activated?
By studying the structure of cellular receptors and of the molecules that activate them, scientists at the Universities of Geneva and Basel are deciphering the details of immune cell activation. Chemokine receptors, located at the surface of many immune cells, play an important role in their function.
Pharmacology - Health - 16.06.2021
Health - 15.06.2021
Pharmacology - Health - 11.06.2021
Health - Pharmacology - 11.06.2021
Pharmacology - Health - 11.06.2021
Pharmacology - Health - 07.06.2021
Health - Life Sciences - 07.06.2021 
Modelling lungs to limit testing on mice
The UNIGE is awarding its 3R prize to the creator of a cell model which, by reproducing a lung infection, has enabled the identification of a promising treatment. Pseudomonas aeruginosa is a bacterium responsible for many lung infections, particularly in people with cystic fibrosis or a weakened immune system.
Pharmacology - Health - 07.06.2021
Pharmacology - Health - 06.06.2021
Pharmacology - Health - 04.06.2021
Health - Environment - 04.06.2021 
Researchers put technology to work for the global South
Tech4Dev, an EPFL program to develop technology that addresses the specific needs and living conditions of communities in the developing world, has announced four new winning projects for its research grants.
Pharmacology - Health - 04.06.2021
Pharmacology - Health - 04.06.2021
Economics / Business - Health - 04.06.2021
Health - Life Sciences - 03.06.2021 
Better choice of contraceptives can prevent breast cancer
There is a strong link between hormonal contraceptives and breast cancer risk. The main culprit are progestins, synthetic mimics of the pregnancy hormone progesterone that stimulate cell growth in the breast.
Pharmacology - Health - 03.06.2021
Pharmacology - Health - 03.06.2021
Pharmacology - Health - 02.06.2021
Pharmacology - Health - 02.06.2021
Pharmacology - Health - 02.06.2021
Health - Pharmacology - 01.06.2021 
The simulated patient
Digital twins enable customized medical therapies. researchers have now modeled several hundred such avatars based on real people and treated them experimentally.
Pharmacology - Health - 01.06.2021
Health - Environment - 31.05.2021 
Global warming already responsible for one in three heat-related deaths
An international study coordinated by the University of Bern and the London School of Hygiene & Tropical Medicine shows for the first time the actual contribution of man-made climate change in increa
Pharmacology - Health - 28.05.2021
Pharmacology - Health - 27.05.2021
Pharmacology - Health - 25.05.2021
Health - 25.05.2021
Health - Campus - 20.05.2021 
Vice-Rector for Research Daniel Candinas resigns
After more than five years in the University Executive Board, Daniel Candinas will step down as Vice-Rector for Research of the University of Bern at the end of 2021.
Pharmacology - Health - 20.05.2021
Pharmacology - Health - 19.05.2021
Pharmacology - Health - 18.05.2021
Health - 17.05.2021
Campus - Health - 17.05.2021
Pharmacology - Health - 17.05.2021
Health - Innovation - 17.05.2021
Health - Campus - 10.05.2021
Health - Event - 10.05.2021
Environment - Health - 10.05.2021
Health - Social Sciences - 07.05.2021
Pharmacology - Health - 05.05.2021
Health - 03.05.2021
Pharmacology - Health - 03.05.2021
Pharmacology - Health - 01.05.2021
Health - Psychology - 30.04.2021
Pharmacology - Health - 28.04.2021
Health - Life Sciences - 28.04.2021 
Awakening "ghosts" in patients with Parkinson's
Scientists are developing a completely new "brain stress test" for evaluating the mental status of patients with Parkinson's disease, the second most prevalent neurodegenerative disease worldwide. It involves awakening the "ghosts" hidden in specific networks of the brain to predict the onset of hallucinations.
Health
Results 1 - 50 of 2270.
Female researchers on the move
In autumn 2021 a new Centre for biomedical reseach will be inaugurated in Bellinzona. To support this event, Ticino Management features a special series of articles presenting the activities of the two main residents of the facility, IRB and IOR.
In autumn 2021 a new Centre for biomedical reseach will be inaugurated in Bellinzona. To support this event, Ticino Management features a special series of articles presenting the activities of the two main residents of the facility, IRB and IOR.
New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline
All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for =30 seconds, most (11/14) within the WHO wi
All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for =30 seconds, most (11/14) within the WHO wi
By studying the structure of cellular receptors and of the molecules that activate them, scientists at the Universities of Geneva and Basel are deciphering the details of immune cell activation. Chemokine receptors, located at the surface of many immune cells, play an important role in their function.
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intraand extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal noctu
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intraand extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal noctu
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years
Novartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)
Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G 1 ; Phase III clinical trial to start in 2021 Resul
Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G 1 ; Phase III clinical trial to start in 2021 Resul
The UNIGE is awarding its 3R prize to the creator of a cell model which, by reproducing a lung infection, has enabled the identification of a promising treatment. Pseudomonas aeruginosa is a bacterium responsible for many lung infections, particularly in people with cystic fibrosis or a weakened immune system.
Approval for New Alzheimer’s Drug Developed at UZH
The active ingredient aducanumab, which was discovered at the University of Zurich, has been approved for use in the United States as a treatment for Alzheimer's disease.
The active ingredient aducanumab, which was discovered at the University of Zurich, has been approved for use in the United States as a treatment for Alzheimer's disease.
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduc tion of proteinuria 1 - a key risk predictor in kidney disease progressi
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduc tion of proteinuria 1 - a key risk predictor in kidney disease progressi
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June
Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June
Tech4Dev, an EPFL program to develop technology that addresses the specific needs and living conditions of communities in the developing world, has announced four new winning projects for its research grants.
Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2
There is a strong link between hormonal contraceptives and breast cancer risk. The main culprit are progestins, synthetic mimics of the pregnancy hormone progesterone that stimulate cell growth in the breast.
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.
Novartis Kisqali reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to th
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to th
Digital twins enable customized medical therapies. researchers have now modeled several hundred such avatars based on real people and treated them experimentally.
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The sa
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The sa
An international study coordinated by the University of Bern and the London School of Hygiene & Tropical Medicine shows for the first time the actual contribution of man-made climate change in increa
After more than five years in the University Executive Board, Daniel Candinas will step down as Vice-Rector for Research of the University of Bern at the end of 2021.
2020 Annual Report published
With research, teaching and consulting on all aspects of water, Eawag is committed to a sustainable future - in Switzerland and worldwide. This is illustrated by the diverse and exciting projects that we present in our Annual Report. Our new Annual Report shows what the aquatic research institute Eawag has experienced and achieved in this challenging year of 2020.
With research, teaching and consulting on all aspects of water, Eawag is committed to a sustainable future - in Switzerland and worldwide. This is illustrated by the diverse and exciting projects that we present in our Annual Report. Our new Annual Report shows what the aquatic research institute Eawag has experienced and achieved in this challenging year of 2020.
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study 1 Neovascular age-related macular degeneration account
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study 1 Neovascular age-related macular degeneration account
Vaccination - personal values and group dynamics are decisive
How do you get more people to have vaccinations? Gudela Grote firmly believes that it's worth looking at team dynamics.
How do you get more people to have vaccinations? Gudela Grote firmly believes that it's worth looking at team dynamics.
Scientists are developing a completely new "brain stress test" for evaluating the mental status of patients with Parkinson's disease, the second most prevalent neurodegenerative disease worldwide. It involves awakening the "ghosts" hidden in specific networks of the brain to predict the onset of hallucinations.
